BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is on recovery track with 13.01% gain from a 1-year low price of $78.42. The company lost -5.26% to attain the price of $88.62 on Oct. 18, 2017. Throughout the recent session, the prices were hovering between $86.9 and $94.75. These shares are 26.89% off its target price of $112.45 and the current market capitalization stands at $15.53B. The recent change has given its price a -0.88% deficit over SMA 50 and -11.83% deficit over its 52-week high. The stock witnessed -3.78% declines, 1% gains and -1.78% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BMRN’s volatility during a week at 3.49% and during a month it has been found around 2.34%.BioMarin Pharmaceutical Inc. (BMRN) Top Holders
Institutional investors currently hold around $15.78 billion or 0% in BMRN stock. Look at its top three institutional owners. Capital Research Global Investors owns $1.77 billion in BioMarin Pharmaceutical Inc., which represents roughly 11.38% of the company’s market cap and approximately 11.21% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 14,345,027 shares of the stock are valued at $1.34 billion. The third largest holder is Jennison Associates Llc, which currently holds $1.24 billion worth of this stock and that ownership represents nearly 7.98% of its market capitalization.BioMarin Pharmaceutical Inc. 13F Filings
At the end of June reporting period, 204 institutional holders increased their position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by some 13,541,821 shares, 194 decreased positions by 14,428,203 and 64 held positions by 140,683,166. That puts total institutional holdings at 168,653,190 shares, according to SEC filings. The stock grabbed 47 new institutional investments totaling 1,113,512 shares while 37 institutional investors sold out their entire positions totaling 5,949,056 shares.BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insider Trades
Multiple company employees have indulged in significant insider trading. BioMarin Pharmaceutical Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, Technical Operations Baffi Robert has sold 18,415 shares of BioMarin Pharmaceutical Inc. (BMRN) in trading session dated Sep. 28, 2017. These shares are worth $1,702,098 and were traded at $92.43 each. The SEC filing shows that Ajer Jeffrey Robert performed a sale of 3,521 shares. The EVP, Chief Commercial Officer disposed these shares by way of transaction on Sep. 22, 2017. The company’s shares were given away at $95 per share worth to an income of some $334,495 on account of Ajer Jeffrey Robert.
President, Worldwide R&D, Fuchs Henry J, sold 15,000 common shares of BioMarin Pharmaceutical Inc. (BMRN) in the open market. In a transaction dated Sep. 15, 2017, the shares were put up for sale at an average price of $90.5, raking in a sum of $1,357,500. After this sale, 136,422 common shares of BMRN are directly owned by the insider, with total stake valued at $12,089,718.
In the transaction dated Sep. 15, 2017, the great number of shares disposed came courtesy the Director; Lawlis V Bryan disposed a total of 3,750 shares at an average price of $91.26, amounting to approximately $342,225. The insider now directly owns 15,910 shares worth $1,409,944.BioMarin Pharmaceutical Inc. (BMRN) Analyst Guide
Several analysts have released their opinion on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with 14 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.48 average brokerage recommendation.